List of works - Marc Lémann

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease

scientific article published on 30 July 2008

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

scientific article published on 20 December 2006

Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease.

scientific article published on 7 April 2011

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis

scientific article published on 30 June 2009

CD4+NKG2D+ T Cells in Crohn’s Disease Mediate Inflammatory and Cytotoxic Responses Through MICA Interactions

article

Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease

scientific article published on 20 September 2012

Clinical implications of mucosal healing for the management of IBD.

scientific article published on December 2009

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

scientific article

Development of the Crohn's disease digestive damage score, the Lémann score

scientific article published on 28 November 2010

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health

scientific article published on January 2010

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease

scientific article published on October 2009

Erratum: Corrigendum: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

scholarly article published in Nature Genetics

Erratum: Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Respo

article

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

scientific article

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

scientific journal article

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report

scientific article

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease

scientific article

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy

scientific article published on 20 August 2010

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

scientific article

List of works by Marc Lémann

A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease.

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis

CD4+NKG2D+ T Cells in Crohn’s Disease Mediate Inflammatory and Cytotoxic Responses Through MICA Interactions

Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease

Clinical implications of mucosal healing for the management of IBD.

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Development of the Crohn's disease digestive damage score, the Lémann score

Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease

Erratum: Corrigendum: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Erratum: Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Respo

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?